About Gene Thrive

Advancing Innovation, Transforming Lives: The Future of Gene Therapy Starts Here

Welcome to GeneThrive, where innovation meets inspiration in the dynamic realm of gene therapy. As a premier summit in the field, GeneThrive is dedicated to fostering collaboration, sparking creativity, and accelerating progress in genetic medicine.

GeneThrive brings together a diverse community of scientists, clinicians, entrepreneurs, investors, and policymakers, united by a shared passion for harnessing the power of genes to revolutionize healthcare. Our summit serves as a vibrant platform for thought leaders and trailblazers to exchange ideas, share cutting-edge research, and explore emerging trends shaping the future of gene therapy.

With a focus on inclusivity and interdisciplinary collaboration, GeneThrive cultivates a supportive environment where experts from various disciplines come together to address key challenges and seize opportunities in gene therapy. Through engaging keynotes, interactive workshops, insightful panel discussions, and networking opportunities, GeneThrive empowers attendees to drive innovation, overcome obstacles, and make meaningful contributions to the advancement of genetic medicine.

Speaker Application Form

Join us at Gene Thrive 2025 and embark on a transformative journey where innovation flourishes, connections grow, and the future of gene therapy is shaped by the collective efforts of visionary individuals committed to advancing science, overcoming challenges, and revolutionizing healthcare.

Gene Thrive 2025 Speakers

Speaker 1
Eric B. Kmiec PhD

Executive Director & Chair, Geno Editing Institute

PLENARY SPEAKER

Speaker 2
Kevin Davies PhD

Executive Editor, The CRISPR Journal

Speaker 3
Brian O’Mahony

Chief Executive, Irish Haemophilia Society

Speaker 4
Cedric Hermans

Professor, Haemostasis and Thrombosis Unit

Why Attend Gene Thrive 2025

GeneThrive 2025 offers a unique opportunity for professionals across various sectors to come together and participate in a transformative event focused on gene therapy. Here are several compelling reasons why individuals should attend:

Stay Updated on the Latest Advancements

Gene Thrive provides access to cutting-edge research and breakthrough technologies.

Networking and Collaboration

A platform for networking and collaboration among industry leaders, researchers, and other stakeholders.

Professional Development

Gain invaluable insights and skills through keynote presentations, discussions, and interactive sessions.

Access to Expertise

Engage with experts, thought leaders, and key opinion leaders in the gene therapy field.

Influence and Impact

Influence the direction of gene therapy advancements and policy shaping future developments.

Inspiration and Motivation

Be inspired by innovative research and patient success stories, fueling your own passion in the field.

Agenda at a Glance

CRISPR and Beyond: Innovations in Gene Editing

This session will delve into the latest advancements in gene editing technologies, including CRISPR/Cas9, base editing, and prime editing. Experts will discuss their applications in therapeutic development, challenges, and future prospects.

Precision Gene Editing with Base Editors

This subsession will focus on base editing technologies, which enable precise, single-nucleotide changes in the genome without inducing double-strand breaks. Experts will discuss the principles, applications, and limitations of base editing, as well as recent innovations and future prospects.

Prime Editing: Rewriting the Genetic Code

This subsession will explore prime editing, a revolutionary genome editing technology that enables the precise insertion, deletion, or substitution of DNA sequences with unprecedented accuracy and efficiency. Experts will discuss the underlying mechanisms, applications, and challenges of prime editing, as well as its potential for therapeutic interventions.

Next-Generation Gene Editing Platforms

Description: This subsession will highlight emerging gene editing platforms and technologies that complement or enhance existing tools like CRISPR. Topics may include homing endonucleases, transposon-based systems, and synthetic nucleases, as well as their applications in basic research and therapeutic development.

Viral Vectors: Engineering the Perfect Carrier

This subsession will focus on viral vectors as one of the most commonly used gene delivery systems in gene therapy. Experts will discuss strategies for engineering viral vectors, optimizing their safety and efficiency profiles, and overcoming immune responses and other challenges associated with their use.

Non-Viral Delivery Systems

This subsession will explore non-viral gene delivery systems, including liposomes, nanoparticles, polymers, and cell-penetrating peptides. Experts will discuss the advantages, limitations, and recent advancements in non-viral vectors, as well as strategies for enhancing their delivery efficiency and target specificity.

Genome Editing Delivery: CRISPR Carriers

This subsession will focus on the delivery of CRISPR-Cas systems for genome editing applications. Experts will discuss different delivery strategies, including viral and non-viral approaches, as well as challenges and opportunities for optimizing CRISPR delivery to target cells and tissues.

Targeted Delivery: Precision Medicine Approaches:

This subsession will explore strategies for achieving targeted delivery of gene therapies to specific cells or tissues while minimizing off-target effects. Experts will discuss ligand-mediated targeting, tissue-specific promoters, and other precision medicine approaches for enhancing the specificity and efficacy of gene delivery systems.

Genetic Disorders: Therapeutic Breakthroughs:

This subsession will focus on the clinical applications of gene therapy for treating genetic disorders, such as cystic fibrosis, muscular dystrophy, and sickle cell disease. Experts will discuss recent therapeutic breakthroughs, ongoing clinical trials, and challenges in translating gene therapies from preclinical studies to clinical practice.

Cancer Immunotherapy: Targeting Tumor Cells: Advances in Base Editing:

This subsession will explore the use of gene therapy for cancer immunotherapy, including adoptive cell transfer, chimeric antigen receptor (CAR) T-cell therapy, and oncolytic viruses. Experts will discuss the latest advances, clinical outcomes, and future directions in utilizing gene-based approaches to target and eradicate cancer cells.

Neurodegenerative Diseases: Promising Interventions:

This subsession will examine the potential of gene therapy for treating neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). Experts will discuss novel gene delivery strategies, gene editing technologies, and emerging therapeutic targets for addressing the underlying causes of neurological disorders.

Infectious Diseases: Gene-Based Strategies:

This subsession will focus on the use of gene therapy for combating infectious diseases, including viral infections, bacterial infections, and emerging pathogens. Experts will discuss gene-based strategies for vaccine development, antiviral therapies, and immune modulation, as well as the potential role of gene editing in targeting infectious agents and enhancing host resistance.

Informed Consent and Autonomy

This subsession will explore the ethical principles of informed consent and patient autonomy in the context of gene therapy trials. Experts will discuss challenges in obtaining meaningful consent, ensuring comprehension of risks and benefits, and protecting vulnerable populations participating in clinical research.

Equity and Access

This subsession will examine issues of equity and access in the delivery of gene therapy interventions. Experts will discuss barriers to access, including cost, insurance coverage, and disparities in healthcare delivery, and explore strategies for promoting equitable access to gene therapies for all patients in need.

Privacy and Genetic Data

This subsession will address the ethical and legal challenges surrounding the collection, storage, and use of genetic data in gene therapy research and clinical practice. Experts will discuss privacy concerns, data security risks, and regulatory frameworks for protecting genetic privacy and ensuring responsible data stewardship.

Social and Cultural Implications

This subsession will explore the social and cultural dimensions of gene therapy, including perceptions, beliefs, and values that may influence acceptance or resistance to genetic interventions. Experts will discuss approaches to fostering culturally sensitive and inclusive practices in gene therapy research, education, and healthcare delivery.

Next-Generation Therapeutic Modalities:

This subsession will highlight emerging therapeutic modalities that complement or extend the capabilities of gene therapy. Experts will discuss innovative approaches such as RNA-based therapies, gene editing in vivo, and synthetic biology, as well as their potential applications and challenges.

Personalized Medicine and Gene Editing:

This subsession will explore the intersection of gene editing technologies and personalized medicine. Experts will discuss advances in genome sequencing, biomarker identification, and patient stratification, as well as the potential of precision gene editing to tailor therapies to the unique genetic makeup of individual patients.

Gene Therapy for Rare Diseases:

This subsession will focus on the role of gene therapy in addressing rare and orphan diseases with unmet medical needs. Experts will discuss strategies for accelerating the development of gene therapies for rare diseases, including regulatory pathways, patient advocacy, and collaborative research efforts.

Regulatory and Policy Landscape:

This subsession will examine the evolving regulatory and policy landscape surrounding gene therapy research, development, and commercialization. Experts will discuss regulatory challenges, policy implications, and future directions for ensuring the safe and ethical implementation of gene therapy technologies.

Interested in Sponsoring Gene Thrive 2025?

If your company is interested in sponsoring Gene Thrive 2025, we would be delighted to discuss the opportunities with you. Please send us a quick email, and we will promptly provide you with more information and our sponsorship brochure.

Venue



Hilton Boston/Woburn

2 Forbes Rd, Woburn, MA 01801,
United States

Contact

Address

259, Narendra Colony, Hyderabad, Telangana 502032

Call Us

+91 9059841607

Email Us

jyothi@pharmasynergevents.com

Loading
Your message has been sent. Thank you!

Our Newsletter

Subscribe to our newsletter and receive the latest news about our products and services!

Loading
The email verification link has been sent to your email address. Please verify to subscribe with our newsletter!